Prism Medico & Pharmacy shareholders approved a strategic investment in M/s. Infuze Well Private Limited during its 24th Annual General Meeting on September 19, 2026. The meeting also saw the adoption of financial statements for FY26 and the re-appointment of key board members.

Mrs. Sakshi Laller, Wholetime Director, chaired the proceedings. The meeting was convened through Video Conferencing/Other Audio-Visual Means and concluded at 12:42 pm. As on the record date of September 12, 2026, the company had 4,220 shareholders. No queries were raised by shareholders during the meeting.

Governance and Audit Appointments

The Board of Directors secured shareholder approval for several critical governance roles. Mr. Davender Singh (DIN: 09447213), who retired by rotation, was re-appointed as a Director.

M/s. Garg Mendiratta and Associates, Chartered Accountants, were re-appointed as statutory auditors with their remuneration fixed by the members. Additionally, the company appointed M/s. SDK & Associates, Practicing Company Secretaries, as Secretarial Auditors for a five-year term spanning from FY27 to FY31.

Strategic Investment in Infuze Well

A significant portion of the special business involved approving transactions related to M/s. Infuze Well Private Limited. Shareholders authorized:

• Variation in the objects of the Preferential Issue and utilization of proceeds, previously approved at the Extraordinary General Meeting on March 20, 2026.
• Investment of funds in Infuze Well securities under Section 186 of the Companies Act, 2013.
• Subscription to equity shares of Infuze Well as a material related-party transaction.
• General approval for related party transactions.

These approvals indicate a structured approach to deploying capital into the private entity, aligning with the varied use of proceeds from earlier preferential issues.

Financial Statements Adoption

Members received, considered, and adopted the Audited Standalone Financial Statements for the financial year ended March 31, 2026. This included the Reports of the Board of Directors and Auditors thereon, concluding the routine annual compliance requirements for the period.

Voting Process

The company utilized National Securities Depositories Limited (NSDL) for remote e-voting and voting during the AGM. Remote e-voting commenced at 9:00 am on September 16, 2026, and ended at 5:00 pm on September 18, 2026. M/s. M.R. Chechi & Associates, Practicing Company Secretaries, were appointed as Scrutiniser for the voting process.

Prism Medico & Pharmacy has scheduled its 24th Annual General Meeting (AGM) for Saturday, September 19, 2026. The company seeks shareholder approval for a strategic investment of up to ₹23 crore in M/s. Infuze Well Private Limited (IWPL). This follows a Board of Directors meeting held on Monday, August 24, 2026, at its registered office in Sirmaur, Himachal Pradesh.

The session concluded with the approval of the Director’s Report and annexures for the financial year ended March 31, 2026. This approval paves the way for the announcement of the company’s annual financial results and the finalization of the AGM agenda.

Annual General Meeting Details

The board fixed the date for the AGM as Saturday, September 19, 2026. The meeting will be conducted via Video Conferencing or Other Audio-Visual Means, starting at 12:30 pm.

Key logistical dates approved by the board include:

• Register Closure: The Register of Members and Share Transfer Books will remain closed from September 13, 2026, to September 19, 2026 (both days inclusive).
• E-Voting Cut-off: September 12, 2026, is the cut-off date for shareholders to record their entitlement to cast electronic votes.
• Scrutinizer: Mr. Mast Ram Chechi, proprietor of M/s. M. R. Chechi and Associates (Company Secretaries, Chandigarh), was appointed as the scrutinizer for the e-voting process.

E-Voting Schedule

Shareholders can participate in remote e-voting during the specified window. The timeline is as follows:

Auditor Appointments

The board considered and recommended the following auditor appointments:

• Statutory Auditors: Re-appointment of M/s. Garg Mendiratta and Associates (Chartered Accountants) with remuneration fixed.
• Secretarial Auditors: Appointment of M/s. SDK & Associates (Practicing Company Secretaries) for five financial years, from FY27 to FY31.

Preferential Issue Variation and Strategic Investment

A significant corporate governance update was the approval of a variation in the objects of the Preferential Issue and the utilization of its proceeds. This change modifies the terms originally approved by members in the Extraordinary General Meeting held on March 20, 2026.

The board proposed diverting ₹23 crore of the preferential issue proceeds—originally earmarked for plant machinery and civil structures—to acquire a controlling stake in IWPL. IWPL is setting up a Large Volume Parenteral (LVP) manufacturing facility in Naraingarh, Haryana.

Transaction Details

The investment constitutes a material related party transaction as IWPL is wholly owned by Mrs. Sakshi Laller, Whole-Time Director of Prism Medico, and her immediate family. Mrs. Laller holds 19.40% of IWPL’s paid-up equity share capital. Consequently, related parties are required to abstain from voting on this resolution.

The deployment of proceeds towards this revised object is contingent upon the receipt of balance consideration payable on the exercise of convertible warrants allotted in the earlier preferential issue. The company has received ₹17.5 crore till date against the total ₹25 crore raised, with ₹7.5 crore remaining to be realized upon warrant exercise.

Additionally, the board recommended investing the company’s funds in accordance with Section 186 of the Companies Act, 2013, noting that the proposed investment exceeds the statutory limits prescribed under Section 186(2).

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.